In a 24-week post hoc ENHANCE analysis, ensifentrine improved symptoms, dyspnea, and quality of life for stable COPD patients ...
The post hoc analysis of the AGAVE-201 trial found that axatilimab demonstrated consistent response rates in patients with chronic graft-vs-host disease (GVHD), regardless of the number or type of ...
SAN DIEGO--(BUSINESS WIRE)--Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients ...
Amicus Therapeutics has released a post-hoc analysis from the PROPEL study, published in Muscle and Nerve, which evaluated the efficacy of cipaglucosidase alfa-atga combined with miglustat (cipa+mig) ...
Consistency of BMD gains presented at NAMS 2025 demonstrate EB613’s efficacy in both young postmenopausal women and in women ...
Patients at high risk for cardiovascular disease are less likely to lose days to death when treated with icosapent ethyl than ...
Endeavor BioMedicines Presents New Clinical Findings From Post Hoc Analysis of Phase 2a Clinical Trial Evaluating ENV-101 in Patients with Idiopathic Pulmonary Fibrosis Findings presented at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback